[{"orgOrder":0,"company":"Undisclosed","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Controlled Substance","year":"2022","type":"Acquisition","leadProduct":"Fentanyl","moa":"||Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"Undisclosed \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Adalvo"},{"orgOrder":0,"company":"University of Cologne","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Fentanyl","moa":"||Mu opioid receptor","graph1":"Oncology","graph2":"Phase II","graph3":"University of Cologne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Buccal Tablet","sponsorNew":"University of Cologne \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"University of Cologne \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Levobupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Epidural","sponsorNew":"Hamad Medical Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"October 6 University","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Fentanyl","moa":"||Mu opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Epidural","sponsorNew":"Egymedicalpedia \/ October 6 University","highestDevelopmentStatusID":"6","companyTruncated":"Egymedicalpedia \/ October 6 University"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atropine","moa":"||Muscarinic acetylcholine receptor M3 | Muscarinic acetylcholine receptor M2 | Muscarinic acetylcholine receptor M1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"UT Southwestern Medical Center \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"UT Southwestern Medical Center \/ Chiesi Group"},{"orgOrder":0,"company":"Lee Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Fentanyl","moa":"||Mu opioid receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Lee Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lee Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Lee Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Duragesic (TN)

Duragesic (TN)
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Duragesic (TN)

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

31 API Suppliers, 11 USDMF, 11 CEP/COS, 3 JDMF, 1 EU WC, 4 KDMF, 13 NDC API, 10 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

18 Drugs in Development

18 Drugs in Development

INTERMEDIATES

4 Intermediate Suppliers

4 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

498 FDF Dossiers, 71 FDA Orange Book, 392 Europe, 5 Canada, 2 South Africa, 28 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 4 DKSH, 2 Boai NKY Pharmaceuticals Ltd, 1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Alcedo Pharmachem, 5 BASF, 1 Huzhou Sunflower Pharmaceutical, 1 Microlex e.U, 1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical, 6 Fillers, Diluents & Binders, 5 Direct Compression, 4 Thickeners and Stabilizers, 4 Rheology Modifiers, 3 Film Formers & Plasticizers, 2 Solubilizers, 2 Granulation, 1 Controlled & Modified Release, 1 Taste Masking, 1 Coating Systems & Additives

DIGITAL CONTENT

209 News #PharmaBuzz

209 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 370 Regulatory FDF Prices, 21 Annual Reports

MARKET PLACE

5 APIs, 21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 5 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 11 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Lee Pharma

India

CPhI WW Frankfurt

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Lead Product(s) : Fentanyl,Inapplicable

Therapeutic Area : Oncology

Study Phase : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

Details : Undisclosed

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 01, 2025

Lead Product(s) : Fentanyl,Inapplicable

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Ethypharm

France

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Lead Product(s) : Fentanyl,Inapplicable

Therapeutic Area : Neurology

Study Phase : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer

Details : Undisclosed

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 30, 2013

Lead Product(s) : Fentanyl,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Phase III

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Hamad Medical Corporation

Country

EPSC

Not Confirmed

04

Egymedicalpedia

Country

EPSC

Not Confirmed

05

Undisclosed

Country

EPSC

Not Confirmed

06

UT Southwestern Medical Center

U.S.A

EPSC

Not Confirmed

07

University of Cologne

Country

EPSC

Not Confirmed

08

CIUSSS de l'Est-de-l'Île-de-Montréal

Country

EPSC

Not Confirmed

09

Indivior

U.S.A

EPSC

Not Confirmed

10

R-Pharm

Country

EPSC

Not Confirmed

1
2